Table 1.
Baseline pre-HCT characteristics of evaluable subjects.
| Variables | N = 47 | % |
|---|---|---|
| Age, y | ||
| <40 | 9 | 19.1 |
| 40–64 | 28 | 59.6 |
| ≥65 | 10 | 21.3 |
| Sex | ||
| Female | 16 | 34 |
| Male | 31 | 66 |
| Primary diagnosis | ||
| Acute lymphoblastic leukemia | 5 | 10.6 |
| Acute myeloid leukemia | 11 | 23.4 |
| Chronic lymphocytic leukemia | 3 | 6.4 |
| Chronic myelogenous leukemia | 2 | 4.3 |
| Hodgkin’s disease | 3 | 6.4 |
| Myelodysplastic syndrome | 9 | 19.1 |
| Multiple myeloma | 3 | 6.4 |
| Myeloproliferative syndromes | 2 | 4.3 |
| Non-Hodgkin lymphoma | 9 | 19.1 |
| Disease Risk Index (DRI) | ||
| Low | 3 | 6.4 |
| Intermediate | 25 | 53.2 |
| High/very high | 19 | 40.4 |
| Conditioning intensity | ||
| Myeloablative | 23 | 48.9 |
| Reduced intensity/nonmyeloablative | 24 | 51.1 |
| KPS | ||
| ≤80 | 5 | 10.6 |
| >80 | 42 | 89.4 |
| FEV1 | ||
| ≤80 | 10 | 21.3 |
| >80 | 37 | 78.7 |
| DLCO | ||
| >80% | 6 | 12.8 |
| 66%−80% | 27 | 57.4 |
| ≤65% | 14 | 29.8 |
| Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) | ||
| 0 | 3 | 6.4 |
| 1–2 | 25 | 53.2 |
| ≥3 | 19 | 40.4 |
| Match grade | ||
| 8/8 | 40 | 85.1 |
| Other | 7 | 14.9 |
| Baseline Body Mass Index | ||
| <30 | 38 | 80.9 |
| ≥30 | 9 | 19.1 |